Pulling SEC filings + quote and writing the call…

Autolus Therapeutics plc
Next earnings Aug 10, 2026 · consensus $-0.24 EPS, $30.8M rev
Last earnings -7.0% on 2026-05-14
Revenue grew 644.9% YoY; but unprofitable (net margin -381.4%).
Autolus Therapeutics plc shows $75.4M in FY2025 revenue (+644.9% YoY), a -381.4% net margin, and -161.4% ROE.
Sources: SEC EDGAR (CIK 0001730463, latest 10-Q filed 2026-05-14) · EODHD · as of 6/24/2026, 11:00:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $10.1M | $75.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$141M | -$143M | -$180M | -$241M | -$271M |
| Net income | -$142M | -$149M | -$208M | -$221M | -$288M |
| Diluted EPS | -$1.97 | -$1.57 | -$1.20 | -$0.86 | -$1.08 |
| Net margin | — | — | — | -2180.5% | -381.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.